YTHDF1 and acute myeloid leukemia: Tegaserod blocked YTHDF1 binding with m6A-modified mRNAs, suppressing YTHDF1-mediated translation of Cyclin E2, thus reducing the viability of patient-derived AML cells in vitro, eventually extending survival in patient-derived xenograft models [442].